未登录

Y

Yuji Sato

jcr pharmaceuticals

H指数:14

被引数:822

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

帕比司他法（Pabinafusp alfa）治疗粘多糖贮积症II型时酶替代疗法中的输注速率调整

British Journal of Clinical Pharmacology

IF3

2026-05-170

OAAI

Long-term impact of pabinafusp alfa on disease burden in Hunter syndrome: A 4-year follow-up of patient-reported outcomes

MOLECULAR GENETICS AND METABOLISM

IF3.5

2025-02-010

PRE

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2024-03-072

OAAI

On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II ( Vol 141, 108143, 2024)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-03-010

OAAI

On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-03-011

PRE

α- L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial

MOLECULAR THERAPY

IF12

2024-03-011

OA

Efficacy and safety data (52-week) from a phase 1/2 trial and extension study of JR-171 (lepunafusp alfa) used in enzyme replacement therapy for patients with MPS I

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

Integrated long-term efficacy and safety data on enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis type II (MPS II): Updated clinical data from Japan and Brazil

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

A global phase III study of pabinafusp alfa (JR-141) for neuronopathic mucopolysaccharidosis type II: Updated study design

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

A phase I/II clinical trial of JR-441 for treatment of Sanfilippo syndrome type A (MPS IIIA)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

IF5.5

2022-06-1113

OAAI

A phase I/II clinical study of intravenous administration of JR-171, a blood-brain barrier-crossing enzyme, in mucopolysaccharidosis type I: An update

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-010

PRE

Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid

METABOLIC BRAIN DISEASE

IF3.5

2022-01-2815

OAAI

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil

MOLECULAR THERAPY

IF12

2021-07-0130

OAAI

Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): Phase III global clinical trial design

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Drug delivery across the blood-brain barrier and resultant reduction of heparan sulfate in the cerebrospinal fluid in the patients with Hunter syndrome (MPS II): An integrated analysis of 25-week Japanese and Brazilian data on pabinafusp alfa (JR-141)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II

MOLECULAR THERAPY

IF12

2021-02-0193

OAAI

Results from a phase 2 trial of a blood-brain barrier penetrating enzyme (JR-141) in patients with MPS II in Brazil

MOLECULAR GENETICS AND METABOLISM

IF3.5

2020-02-010

PREAI

Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): 26-week results from a phase 3 study in Japan suggesting significant efficacy against central nervous system and systemic symptoms

MOLECULAR GENETICS AND METABOLISM

IF3.5

2020-02-010

PREAI

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial

MOLECULAR THERAPY

IF12

2019-02-01110

OAAI